04.18.16
Joseph Horrigan has been appointed chief medical officer, AMO Pharma Ltd.
Dr. Horrigan has more than two decades of experience in the pharmaceutical industry and as a pediatric neuropsychiatrist. Dr. Horrigan has held multiple leadership positions in pharmaceuticals and medical research. Most recently he led clinical development programs in neurodevelopmental disorders at Neuren Pharmaceuticals, and he also co-founded and led the company-wide Medicines for Children Advisory Network at GlaxoSmithKline and served as assistant vice president and head of medical research at Autism Speaks.
Also, Alison McMorn was named vice president of clinical operations and Bernard Kiernan was appointed head of pharmaceutical sciences and manufacturing. Dr. McMorn has an extensive background in managing global clinical development programs and most recently was director of clinical programs at Shire Pharmaceuticals. Mr. Kiernan has more than 20 years of experience in pharmaceuticals and joins the company from Shire Pharmaceuticals, where he was director for product development in global pharmaceutical sciences.
"We are delighted to announce these additions to the AMO Pharma leadership team as the company continues to build momentum and advance our clinical stage development programs targeting new therapies for debilitating diseases including fragile X syndrome and myotonic dystrophy," said Mike Snape, chief executive officer and a founding director of AMO Pharma. "Dr. Horrigan, along with Dr. McMorn and Mr. Kiernan, bring a wealth of expertise in all phases of drug development and clinical research that will be an important asset for us as we continue to advance our current development programs and as we work to identify and acquire new assets for development in the years ahead."
Dr. Horrigan has more than two decades of experience in the pharmaceutical industry and as a pediatric neuropsychiatrist. Dr. Horrigan has held multiple leadership positions in pharmaceuticals and medical research. Most recently he led clinical development programs in neurodevelopmental disorders at Neuren Pharmaceuticals, and he also co-founded and led the company-wide Medicines for Children Advisory Network at GlaxoSmithKline and served as assistant vice president and head of medical research at Autism Speaks.
Also, Alison McMorn was named vice president of clinical operations and Bernard Kiernan was appointed head of pharmaceutical sciences and manufacturing. Dr. McMorn has an extensive background in managing global clinical development programs and most recently was director of clinical programs at Shire Pharmaceuticals. Mr. Kiernan has more than 20 years of experience in pharmaceuticals and joins the company from Shire Pharmaceuticals, where he was director for product development in global pharmaceutical sciences.
"We are delighted to announce these additions to the AMO Pharma leadership team as the company continues to build momentum and advance our clinical stage development programs targeting new therapies for debilitating diseases including fragile X syndrome and myotonic dystrophy," said Mike Snape, chief executive officer and a founding director of AMO Pharma. "Dr. Horrigan, along with Dr. McMorn and Mr. Kiernan, bring a wealth of expertise in all phases of drug development and clinical research that will be an important asset for us as we continue to advance our current development programs and as we work to identify and acquire new assets for development in the years ahead."
